Clinical Trial Update: A First-in-human Study of PARP1 Selective Inhibitor, IMP1734, in Participants With Advanced Solid Tumors [Phase 1, Phase 2]

View source ↗

Summary

This clinical trial update describes a first-in-human study of IMP1734, a PARP1 selective inhibitor, in participants with advanced solid tumors, currently enrol…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Solid Tumors

Drugs mentioned

• IMP1734 (IMP1734)

Snippet

Sponsor: Eikon Therapeutics | Conditions: Advanced Solid Tumor | Phase 1, Phase 2 | Status: RECRUITING